EMJ GOLD

Filter Advertise With Us

Plane flying over the Gulf but avoiding it

The Middle East conflict: pharma’s supply chain stress test

The conflict is disrupting critical air freight routes, exposing vulnerabilities for biologics and low-margin generics.

Does pharma have the power to turn back time?

Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.

Roundtable: How can pharma close the gender health gap?

Robyn Widenmaier (GSK) and Tabetha Sundin (AstraZeneca) discuss whether bids to improve gender parity could be the ticket to change in women’s health.

Get ready for Gen Z doctors

A new generation of doctors is making their way into the workforce, but is the pharmaceutical industry ready to change its tactics to engage these younger HCPs?

Has medical affairs reached 'strategic pillar' standing?

The value of medical affairs is not up for debate, but are companies allocating enough time and resources to make it the strategic function it can be?

VPAG: the UK's ticket to pharma superpower status?

A deal ends months of wrangling between the UK government and the ABPI, but what will it mean for the industry and the UK’s bid to become a life sciences superpower?

Roundtable: Was it worth the risk?

With compliance and regulatory hoops to jump through, medical affairs teams can be reluctant to try new tactics. This roundtable uncovers their relationship with risk and asks what the future holds.

Dr Peter Ahnesorg on why leaders must never stop learning

Peter Ahnesorg, Global Hematology Franchise Head, Roche, talks about his background in biochemistry, his hopes for the haematology space and his approach to leadership.

Hematology: where's it been and where's it going?

Discover the past and future of hematology. Uncover the challenges, advancements, and the industry’s commitment to patient well-being.

Loading posts...

« Previous 1 … 6 7 8 9 10 … 36 Next »